Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer

Melanie S Flint; David M O'Malley; Domenica Lorusso; Susan K Lutgendorf; Alexander B Olawaiye; Adrian M Jubb; Premal H Thaker

doi:10.1158/0008-5472.CAN-25-4426

Back

Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer

Journal article

Open access

Peer reviewed

Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer

Melanie S Flint, David M O'Malley, Domenica Lorusso, Susan K Lutgendorf, Alexander B Olawaiye, Adrian M Jubb and Premal H Thaker

Cancer research (Chicago, Ill.)

05/22/2026

DOI: 10.1158/0008-5472.CAN-25-4426

PMID: 42171510

Files and links (1)

url

https://doi.org/10.1158/0008-5472.CAN-25-4426View

Published (Version of record) Open Access

Abstract

Glucocorticoid receptor (GR) signaling is critical to our physiology but is dysregulated in cancer by the pain, psychological distress, iatrogenic morbidity, and pathology associated with an advanced, invasive disease. Many tumors exploit glucocorticoid signaling to provide anti-apoptotic survival signals, stimulate growth and metastasis, suppress immune surveillance, and drive treatment resistance. Endogenous cortisol and exogenous glucocorticoids are typically associated with poor responses to cytotoxic chemotherapy, targeted therapy, and immunotherapy in patients with solid tumors. Translational and non-clinical data show that selective GR antagonists (SGRAs) synergize with anti-cancer agents, including taxanes, androgen receptor inhibitors, PARP inhibitors, and anti-PD(L)-1 immune checkpoint inhibitors, driving improved anti-cancer activity. In a tumor-intrinsic manner, SGRAs downregulate the anti-apoptotic proteins SGK1 and DUSP1, which induce resistance to cytotoxic chemotherapy. This synergy has been confirmed in several randomized controlled trials, which showed improved efficacy when SGRAs were added to standard-of-care taxane therapy in platinum-resistant ovarian cancer. In a distinct cellular context, SGRAs inhibit resistance to anti-androgen therapy mediated through the GR and have the potential for additive anti-cancer activity in prostate cancer. Herein, we summarize the role of glucocorticoid signaling in solid tumor biology, providing mechanistic insights into recent clinical advances and emphasizing key outstanding translational and clinical questions.

Details

Title: Subtitle: Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer
Creators: Melanie S Flint - Brighton Hospital
David M O'Malley - Ohio State University Hospital
Domenica Lorusso - Humanitas University
Susan K Lutgendorf - University of Iowa
Alexander B Olawaiye - University of Pittsburgh Medical Center
Adrian M Jubb - Corcept Therapeutics (United States)
Premal H Thaker - Washington University in St. Louis
Resource Type: Journal article
Publication Details: Cancer research (Chicago, Ill.)
DOI: 10.1158/0008-5472.CAN-25-4426
PMID: 42171510
NLM abbreviation: Cancer Res
ISSN: 1538-7445
eISSN: 1538-7445
Publisher: American Association for Cancer Research
Language: English
Electronic publication date: 05/22/2026
Academic Unit: Psychological and Brain Sciences; Iowa Neuroscience Institute; Obstetrics and Gynecology; Urology
Record Identifier: 9985164606102771

Metrics

1 Record Views